VYGR SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 7, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 9, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 10, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Voyager Therapeutics Reports Third Quarter 2026 Financial and Operating Results

Nov 5, 2026

8-K

Voyager Therapeutics Appoints Robin Swartz as President and Future CEO

Oct 21, 2026

8-K

Voyager Therapeutics Reports Second Quarter 2026 Financial Results and Pipeline Progress

Aug 6, 2026

8-K

Voyager Therapeutics Presents Positive Preclinical Data for Alzheimer’s Gene Therapy VY1706

Jul 13, 2026

8-K

Voyager Therapeutics Announces Results of 2026 Annual Meeting and Authorized Share Increase

Jun 10, 2026

8-K

Voyager Therapeutics Receives FDA Clearance for VY1706 IND Application

Jun 1, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B3

UPDATED | ATM | Offering amount: $100,000,000

Dec 1, 2025

424B5

SHELF OFFERING | Shares amount: 7,777,778 | Share price: $9.00 | Warrants amount: 3,333,333 | Offering amount: $99,996,665.67

Jan 8, 2024

424B5

SHELF OFFERING | Share price: $10.77 | Offering amount: $100,000,000.00

Jan 4, 2024

424B3

UPDATED | ATM | Offering amount: $75,000,000.00

Nov 15, 2022

424B3

Shares of our common stock having an aggregate offering price of up to $100,000,000.

Dec 3, 2019

424B5

4,500,000 Shares

Nov 8, 2017

Registrations

TYPE

HEADLINE

FILED AT

S-3

November 2025 SHELF and ATM

Nov 10, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jun 9, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 11, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 6, 2024

S-8

Registration

Feb 28, 2024

Form D - Notice of Exempt Offering of Securities - Item 06b

Jan 17, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 28, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 28, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Apr 10, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 23, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 23, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 25, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Carter Todd Alfred (Reporting)

Nov 3, 2026

Swartz Robin (Reporting)

Nov 3, 2026

SCHEDULE 13G/A

ARMISTICE CAPITAL, LLC (Filed by)

Aug 14, 2026

SCHEDULE 13G/A

INTEGRATED CORE STRATEGIES (US) LLC (Filed by)

Jul 31, 2026

SCANGOS GEORGE A (Reporting)

Jun 11, 2026

MACKEY CATHERINE J (Reporting)

Jun 11, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Dec 2, 2025

CORRESP

Form CORRESP - Correspondence

Nov 26, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Nov 16, 2022

CORRESP

Form CORRESP - Correspondence

Nov 10, 2022

LETTER

Form UPLOAD - SEC-generated letter

Nov 9, 2022

CT ORDER

Form CT ORDER - Confidential treatment order

Feb 25, 2022

Voyager Therapeutics, Inc. VYGR · SEC Filings